首页> 外文期刊>肿瘤学与转化医学(英文) >Papillary serous carcinoma of the uterine cervix:a clinicopathological analysis of 4 cases and a literature review
【24h】

Papillary serous carcinoma of the uterine cervix:a clinicopathological analysis of 4 cases and a literature review

机译:宫颈乳头状浆液性癌4例临床病理分析及文献复习

获取原文
获取原文并翻译 | 示例
       

摘要

Objective To investigate the clinicopathological characteristics and clinical treatment outcomes of patients with papillary serous carcinoma of the uterine cervix (PSCC).Methods In this study, 4 patients with histologically confirmed papillary serous carcinoma of the uterine cervix were retrospectively investigated. Pap smears, human papillomavirus (HPV) screening, tumor marker status, biopsy analysis, and relevant imaging examinations were conducted for the confirmation of primary diagnosis and recurrence. Patients underwent surgery, chemotherapy, or radiotherapy, and survival were the main endpoint.Results The 4 patients were diagnosed with IB1, IB1, IIA, or IIIB disease. Two patients (2/4) presented with recurrence within 18 months after primary therapy. Compared with chemotherapy alone (progressionfree survival (PFS): 11 months), radiotherapy combined with adjuvant chemotherapy showed favorable PFS rates (PFS: 20, 36, 13 months in 3 cases), although valid statistical analysis was not feasible because of the small sample size. The 5-year survival rate was 0%, and the 3-year survival rate was 75%. Our data,in agreement with the literature evidence, showed that the number of moderate-risk and high-risk factors in patients diagnosed with PSCC at an early stage was higher than that in patients diagnosed with common adenocarcinoma/squamous carcinoma of the uterine cervix.Conclusion PSCC has a poor clinical prognosis, and compared with chemotherapy alone, radiotherapy combined with adjuvant chemotherapy may lead to improved PFS.
机译:目的探讨宫颈乳头状浆液性浆液性癌(PSCC)的临床病理特征及临床治疗效果。方法:本研究回顾性分析4例经组织学证实为宫颈乳头状浆液性癌的患者。进行了子宫颈抹片检查,人乳头瘤病毒(HPV)筛查,肿瘤标志物状态,活检分析以及相关的影像学检查,以确认初步诊断和复发。接受手术,化学疗法或放射疗法的患者,以生存为主要终点。结果4例患者被诊断出患有IB1,IB1,IIA或IIIB疾病。两名患者(2/4)在初次治疗后18个月内复发。与单纯化疗(无进展生存期(PFS):11个月)相比,放疗联合辅助化疗显示良好的PFS率(3例中,PFS:20、36、13个月),尽管由于样本量少,有效的统计分析是不可行的尺寸。 5年生存率为0%,3年生存率为75%。我们的数据与文献证据一致,表明在早期诊断为PSCC的患者中,中度和高危因素的数量高于诊断为普通腺癌/宫颈鳞状细胞癌的患者。结论PSCC临床预后较差,放疗联合辅助化疗与单纯化疗相比可改善PFS。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号